Company: PACB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001299130-25-000156
Chunk: 39

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 39
---
 upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Shares issuable upon conversion of convertible senior notes61,41531,06361,41531,063Equity awards44,64333,37044,64333,370See Note 7. Equity Plans and Share-Based Compensation for detailed information on equity awards.

NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATIONWe are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker ("CODM") is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.On a regular basis, our CODM reviews:•total revenues by category•total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation•net loss per shareOur assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.

Q2 Fiscal 2025 Form 10-Q25

A summary of the segment profit or loss, including significant segment expenses is as follows:Three Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Total revenue39,766 36,013 76,919 74,823 Less:Cost of revenue25,082 30,075 63,606 57,603 Research and development22,529 38,485 51,582 81,940 Sales and marketing19,516 23,807 39,592 46,344 General and administrative16,659 22,070 36,751 43,286 Impairment charges— 93,200 15,000 93,200 Change in fair value of contingent consideration— — (18,700)(70)Amortization of acquired intangible assets833 4,222 362,875 9,728 Other income, net2,958 2,527 5,515 5,711 Income tax provision (benefit